Introduction {#sec1-1}
============

There is a continuous search for better remedies to combat vitiligo (leucoderma) that is characterized by hypopigmented patches over the body. Though, it is not associated with any major systemic illness, such lesions will lead to social stigma, may affect the psychological status of the individual and has a major impact on self-esteem and perception of the self. Vitiligo is one of the oldest and commonest skin disorders affecting approximately 1--2% of the human population.\[[@ref1]\] Based on the dermatological outpatient\'s records, the incidence of vitiligo is found to be 0.25 to 2.5% in India.\[[@ref2]\]

All skin disorders in Ayurveda are placed under the name of *Kushtha*. In Ayurveda, *Shvitra* is considered as one of the varieties of *Kushtha*,\[[@ref3]\] that can be correlated with vitiligo based on the similarities of signs and symptoms. It is caused due to vitiation of *Tridosha* and *Dhatus* like *Rasa* (lymph), *Rakta* (blood), *Mamsa* (muscles) and *Meda* (fats).\[[@ref4]\] According to *Harita Samhita*, vitiated *Vata* along with *Pitta* affects the *Rakta Dhatu* manifests *Pandura Varna* (whitish patches) on skin that is called as *Shvitra*.\[[@ref5]\] Depending upon chronicity and involvement of deeper tissue (*Dhatus*), disease becomes difficult to treat.

A number of topical formulations are mentioned for management of *Shvitra*. Modern science uses Psoralen + Ultra Violet-A exposure therapy and corticosteroids in the treatment of vitiligo. But they are associated with side effects like burning, itching, nausea, tanning, eye damage, skin aging and skin cancer.\[[@ref6]\] Hence, there is a need to develop an effective formulation with less adverse effects. Ayurveda has ample of formulations that can be used safely in *Shvitra*. *Apamarga Kshara Yoga*\[[@ref7]\] is one of such formulations. In the current study, it is planned to evaluate clinical efficacy of *Apamarga Kshara Yoga* in two different dosage forms i.e. *Lepa* and ointment.

Materials and Methods {#sec1-2}
=====================

The study is a randomized single blind one involving 50 patients with vitiligo fulfilling the inclusion criteria. Each patient was examined in detail. Relevant pathological and biochemical investigations were done before and after treatment and informed consent was taken from all the patients before including into the trial \[[Chart 1](#F1){ref-type="fig"}\]. The study was started after obtaining permission from Institutional Ethics Committee (PGT/7-A/2012-2013/1964/23 dated 21/09/2012) and was registered in Clinical Trial Registry of India (CTRI/2012/11/003157 dated 30/11/2012).

![Consort flow diagram](AYU-36-163-g001){#F1}

Inclusion criteria {#sec2-1}
------------------

Patients having signs and symptoms of *Shvitra* (vitiligo)Patients having age between 16 and 60 yearsPatients with chronicity of \<10 yearsLesions with positive wood\'s lamp test.

Exclusion criteria {#sec2-2}
------------------

Chronicity more than 10 yearsPatients suffering with chronic cardiac, renal, hepatic ailments, insulin-dependent diabetes mellitus (IDDM), non-IDDM and other serious systemic illnessPatches due to burning, chemical explosion,Gravid and lactating womenLesions at *Guhyanga* (genital organ), *Panipadatala* (palms and soles), *Oshtha* (lips), *Ekanga* (involving an entire organ), *Sarvanga* (generalized lesions)\[[@ref8]\]Patches with *Raktaroma* (reddish hair) and *Samsakta* (coalescent).\[[@ref9]\]

Grouping and posology {#sec2-3}
---------------------

Registered patients were grouped into two by using computer generated randomization plan.\[[@ref10]\] Patients of Group A were treated with *Apamarga Kshara Yoga Lepa*,\[[@ref7]\] while patients of Group B were treated with *Apamarga Kshara Yoga* Ointment\[[@ref11]\] \[[Table 1](#T1){ref-type="table"}\]. Patients in both the groups were advised to apply quantity sufficient drug locally on patches in the morning followed by 5--10 min. exposure to sunlight in the morning (before 9 AM) for 8 weeks. Besides, 3 g of *Rasayana Churna*\[[@ref12]\] along with *Madhu* and *Ghrita* was given twice a day as internal medication in both the groups. Patients were advised dietary restrictions during the treatment period.

###### 

Formulation composition of both dosage forms
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Criteria for assessment {#sec2-4}
-----------------------

Scoring pattern was adopted for scrutinizing the symptomatology. The score was given on the basis of Size, Color and Number of patches, Percentage of body area involvement and chronicity of patches \[[Table 2](#T2){ref-type="table"}\]. For the assessment of involvement of body surface area, rule of nine was used to calculate the percentage of lesions with certain modifications. Whole body was scored but looking into the nature of the disease; score was further specified to the organs. Total score was obtained from calculation of [Table 2](#T2){ref-type="table"}. Maximum score was 25. Then obtained score was divided into mild, moderate and severe category.

###### 

Criteria for assessment
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### Severity of disease {#sec3-1}

![](AYU-36-163-g004)

### Criteria for assessment of total effect {#sec3-2}

![](AYU-36-163-g005)

Observations {#sec1-3}
============

Of the registered patients, 26 were in the age group of 16--30 years with chronicity of 1--2 years. Majority of the registered patients (30) were males, 11 had positive family history. Totally, 44 patients had white colored patches while 5 patients had red to white and only one patient had red colored patch. A total of 30 patients had number of patches more than 4; while 12 patients had 4 patches, 2 and 3 patches were found in 6 patients each while only one patient had a single patch. Totally, 12 patients had more than 4 cm size of patches, 4 patients had 4 cm, while 3 patients had 3 cm size of patches, 9 patients had 2 cm and only 2 patients had 1 cm size of patches. *Vata-Kaphaja Prakriti* was predominant in the majority of the patients. Hematological and biochemical investigations after the treatment were within normal limits.

Results {#sec1-4}
=======

Effect of therapy shows that in Group A, 57.26% reduction was found in color of patches, in number of patches 43.80% reduction was found while in percentage area of patches 40.58% reduction was found and 42.42% reduction was found in size of patches \[Figures [1](#F2){ref-type="fig"} and [2](#F3){ref-type="fig"}\]. All these changes were statistically highly significant (*P* \< 0.001) \[[Table 3](#T5){ref-type="table"}\].

![Before treatment (BT) and after treatment (AT) of both Groups; (a) Group B -- BT, (b) Group A -- BT, (c) Group B -- during treatment, (d) Group A -- during treatment, (e) Group B -- AT, (f) Group A -- AT](AYU-36-163-g006){#F2}

![Before treatment (BT) and after treatment (AT) of both Groups (a) Group A -- BT, (b) Group A -- BT, (c) Group A -- AT, (d) Group A -- AT](AYU-36-163-g007){#F3}

###### 

Effect of therapy of patches on Group A (*n*=25)
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In Group B, 55.46% reduction was found in color of patches and 40.42% in number of patches was found. In area of patches 35.53% reduction and 42.45% reduction was found in size of patches that all changes were statistically highly significant (*P* \< 0.001) \[[Table 4](#T6){ref-type="table"} and [Figure 1](#F2){ref-type="fig"}\].

###### 

Effect of therapy on Group B (*n*=25)
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In comparison of both groups, statistically insignificant difference (*P* \< 0.05) was found in the effect of therapies on size, color, number of patches and area of body. Based on this, it can be said that both the dosage forms have similar effect on *Shvitra* (Vitiligo) \[[Table 5](#T7){ref-type="table"}\].

###### 

Comparative effect of therapies on chief complaints
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Discussion {#sec1-5}
==========

Incompatible diet is emphasized to be an important etiological factor in manifestation of *Shvitra*. Charaka also stated that *Papakarma* (Sinful acts), *Guruninda* (Insult of the preceptors)\[[@ref13]\] Such psychological factors may induce stress in the patients and become *Vyanjaka Hetu* (triggering factor) that triggers disease manifestation mechanism. Sudden emotional trauma and depression have been noted to be responsible for sudden onset or rapid spread of lesion.\[[@ref14]\]

In the present study, 47.27% of patients are from the age group of 16--30 years. Though, there is no significance of age with *Shvitra*, but, younger age individuals are more prone to psychological stress and consumption of *Virudhdha Ahara*. According to modern science, it may appear at any age.\[[@ref15]\] As *Shvitra* is *Pittapradhana Tridoshaja Vyadhi*, hence, may be prevalent in the age group of 16-30 years, which is *Pittapradhana*.\[[@ref5]\] 54.55% of patients were males and 45.45% of patients were females. Gender has no role in manifestation of disease.\[[@ref15]\] It is observed that, 80% patients were having negative family history while remaining 20% were having positive family history. It has been mentioned that hereditary diseases (*Sahaja Vyadhi*) are difficult to cure. Modern science says that the occurrence of vitiligo is in ratio of 1:3 when it comes to inheritance.\[[@ref15]\]

*Apamarga Kshara Yoga* has *Apamarga Kshara*, *Ashuddha Manahshila* and *Gomutra* as ingredients. *Ksharas* have qualities like *Ushna* (hot), *Tikshna* (irritant), *Pachana* (digestive), *Vilayana* (corrosive), *Shodhana* (purification), *Ropana* (closure of wound), *Shoshana* (absorbing), *Sthambhana* (restrain), and *Lekhana* (scarificant) etc.\[[@ref16]\] *Apamarga Kshara* has *Tikshna Guna*\[[@ref17]\] so it can remove *Kleda*, *Ama* and *Kapha* and also can clear *Srotodushti* especially *Sanga*. *Manahshila* has *Katu* (pungent), *Tikta Rasa* (bitter taste), *Ushna Virya* and *Singdha* (unctuous), *Guru Guna* (heaviness), *Vata-Kapha Shamana Karma* and also has *Rasayana* and *Varnya Karma*.\[[@ref18]\] It acts on *Bhrajaka Pitta* and helps in restoring normal color of skin. So, may be helpful in vitiligo. Hematological and biochemical parameters of both groups were not affected with the treatment.

Both trial drugs have shown highly significant results in symptoms of *Shvitra*. Comparison in between the groups is statistically insignificant. As complete remission was not found; the duration was increased to 4--6 months in few cases, where the patients were responded significantly. This infers that, there is a need to increase the study period.

Conclusion {#sec1-6}
==========

Both the trial drugs provided significant results against size, color and number of patches. The difference in between the groups is statistically insignificant. Considering the encouraging results, it can be said that both the drugs can be successfully used in cases of *Shvitra*. However, the observations can be revalidated through well-designed clinical trials involving larger sample size. Experiments also can be made to identify responsible factors of the efficacy.
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